SS-31, also known as elamipretide, is the most mechanistically precise agent in this group and the least clinically proven. Its targeting of the inner mitochondrial membrane sets it apart from broad oral supplements such as CoQ10, creatine, and B-vitamin cofactors and from general antioxidants, yet its only FDA approval is a narrow one, as subcutaneous elamipretide (Forzinity) for the rare genetic disease Barth syndrome, granted under accelerated approval in September 2025. Across the full field, regular aerobic and resistance exercise remains the best-validated way to raise mitochondrial capacity, and it is the benchmark the pills and injections are measured against.
| Dimension | SS-31 (elamipretide) | CoQ10 / creatine / B-vitamins | Aerobic + resistance exercise |
|---|---|---|---|
| Mechanism | Targeted, binds cardiolipin | Broad metabolic support | Drives mitochondrial biogenesis |
| Human evidence | Mixed late-stage trials | Decades of use, modest in healthy adults | Large, repeatable adaptation |
| Regulatory status | Approved only for Barth syndrome | Sold as dietary supplements | Not applicable |
| Cost and access | Premium, gray-market | Low, over the counter | No cost |
SS-31 is the most targeted mitochondrial agent but the least proven, holding FDA approval only for Barth syndrome, while established supplements are better documented and exercise carries the strongest evidence of all.
The distinction is location and selectivity. SS-31 is a small peptide engineered to accumulate in the inner mitochondrial membrane, where it binds cardiolipin and stabilizes the cristae that hold the electron transport chain, aiming to cut electron leak at its source. The broad oral supplements act far less selectively, and a precise point of action is a separate matter from the size of the benefit a person actually measures.
SS-31 acts on a single structural target, cardiolipin in the inner mitochondrial membrane, whereas CoQ10, creatine, and B-vitamin cofactors support mitochondrial metabolism through broad, non-selective pathways.
The difference is upstream versus downstream. SS-31 targets cardiolipin so the inner membrane stays organized and fewer reactive oxygen species are produced in the first place, while general antioxidants such as vitamin C and vitamin E react with free radicals only after they have formed. Trials of high-dose antioxidants have shown limited benefit and can even blunt useful adaptations, because a controlled level of reactive oxygen species acts as a signal that drives the body's own repair responses.
| Aspect | Upstream approach (SS-31) | Downstream approach (general antioxidants) |
|---|---|---|
| Point of action | Cardiolipin and membrane structure | Free radicals already released |
| Timing | Before reactive oxygen species form | After they form |
| Effect on ROS signaling | Preserves controlled signaling | Can blunt beneficial signals |
| Human outcome evidence | Not yet shown to improve outcomes | Limited benefit in many trials |
SS-31 works upstream by stabilizing cardiolipin to limit reactive oxygen species at the source, while antioxidants like vitamin C and vitamin E work downstream and have shown limited benefit at high doses in many trials.
On evidence the ranking largely inverts the mechanism ranking. SS-31 has been studied in humans and earned one narrow FDA approval, subcutaneous elamipretide (Forzinity) for Barth syndrome, but its late-stage trials in primary mitochondrial myopathy and in certain eye and heart conditions produced mixed results that left it without approval for general mitochondrial support. A failed or ambiguous Phase 3 trial is heavy evidence rather than a footnote, since it is the most rigorous test an agent can face.
Creatine and CoQ10 rest on decades of human trial data for defined roles, whereas SS-31's largest late-stage trials for general mitochondrial support produced mixed results, leaving it approved only for Barth syndrome.
Regulatory standing is one of the sharpest dividing lines in this comparison. Apart from the narrow approval of subcutaneous elamipretide (Forzinity) for Barth syndrome, SS-31 is an investigational drug with no approval for general mitochondrial support, so outside a trial it moves through a gray market of research-chemical and compounding suppliers where identity, purity, and sterility are not independently guaranteed. CoQ10, creatine, and B vitamins occupy a different category entirely, sold as dietary supplements under manufacturing and labeling rules with third-party-tested options available.
SS-31 is an investigational drug approved only for Barth syndrome and otherwise supplied through unregulated gray-market channels, while CoQ10, creatine, and B vitamins are legally marketed dietary supplements subject to manufacturing and labeling standards.
Route of administration shapes daily use as much as any biochemistry. SS-31 is a peptide that the digestive tract would break down, so it is given by subcutaneous injection, which brings reconstitution of the powder, sterile technique, and cold storage, while CoQ10, creatine, and B vitamins are swallowed as capsules or powders with no special handling. An injected peptide enters circulation directly and predictably, whereas an oral nutrient must survive digestion, which makes uptake more variable but far more convenient.
| Factor | Injectable peptide (SS-31) | Oral supplement (CoQ10, creatine, B-vitamins) |
|---|---|---|
| Route | Subcutaneous injection | Capsule, tablet, or powder |
| Preparation | Reconstitution and sterile technique | None |
| Storage | Cold storage to stay stable | Shelf-stable |
| Absorption | Direct, predictable amount delivered | Variable across the gut wall |
SS-31 requires subcutaneous injection with reconstitution, sterile technique, and cold storage, while CoQ10, creatine, and B vitamins are taken orally with no special handling.
The everyday supplements earn their place through specific, well-characterized roles rather than broad promises. CoQ10 carries electrons in the respiratory chain, creatine recharges ATP through the creatine phosphate system, and B-vitamin cofactors are built directly into the enzymes of energy metabolism. A caveat runs through all three: in people who are not deficient, the measurable benefits tend to be modest, and much of the strong effect seen in studies traces back to correcting an actual deficiency.
CoQ10 serves as a respiratory-chain electron carrier, creatine recharges ATP through the creatine phosphate system, and B-vitamin cofactors are built into energy-metabolism enzymes, though benefits in non-deficient people are generally modest.
Any grounded comparison keeps exercise at the center, because it is the most reliably proven way to raise mitochondrial capacity that exists. Regular aerobic training stimulates mitochondrial biogenesis, increasing the number and density of mitochondria and the tissue's oxidative capacity, while resistance training builds the muscle mass that houses them. This is a large, repeatable adaptation documented across decades of physiology research, which neither the everyday supplements nor an investigational agent like SS-31 can currently claim.
Regular aerobic and resistance exercise produces a large, repeatable increase in mitochondrial density and capacity documented across decades of research, an effect no supplement or investigational agent like SS-31 has matched.
Cost and access tilt heavily toward the established options. CoQ10, creatine, and B vitamins are inexpensive, sold over the counter, and available in third-party-tested forms, so the cost of entry is low and predictable. SS-31 is the opposite on every axis: unapproved for general use and not covered by insurance, it commands a premium through research-chemical and compounding channels, and the headline price omits injection supplies, sterile handling, and the risk that a gray-market vial is underdosed or contaminated.
| Cost factor | SS-31 (elamipretide) | Established supplements | Exercise |
|---|---|---|---|
| Price | Premium, gray-market | Low, over the counter | None |
| Insurance | Not covered for general use | Not applicable | Not applicable |
| Hidden costs | Injection supplies, sterile handling, bad-vial risk | Minimal | None |
| Evidence for the price | Investigational, mixed results | Modest but documented | Strongest of all |
CoQ10, creatine, and B vitamins are low-cost over-the-counter products, while SS-31 commands a premium through gray-market channels for general use, carries hidden injection costs, and is not covered by insurance.
The risk gap is as important as the mechanism gap and points the other way. SS-31's trials provide some short-term safety signal, but its long-term safety, its behavior across diverse populations, and its effect outside controlled studies remain uncertain, and that baseline uncertainty is magnified by gray-market sourcing that carries unverified purity and injection risk. CoQ10, creatine, and B vitamins are far better mapped, with decades of documented use, mild side-effect profiles, and mature quality-testing options.
SS-31 carries unresolved long-term safety questions that are magnified by gray-market sourcing and injection risk, whereas CoQ10, creatine, and B vitamins have decades of documented use with generally mild, well-understood side effects.
Educational use only. This article describes what the published scientific and clinical literature reports about SS-31. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
